Crown Bioscience introduces new in vivo platforms for renal research

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, brings to market a continuum of in vivo platforms for renal disease research.

These platforms include a range of models and help to address the clinical translation of several renal disorders such as polycystic kidney disease (PKD) and diabetic nephropathy.

'CrownBio’s unique end-to-end preclinical support of renal disease research enables us to become a strong strategic partner for pharmaceutical companies. Presently there is no cure for PKD and there is a dire need for preclinical models that can enable better clinical translation of drug discovery efforts,' said Jim Wang, MD, Senior Vice President of cardiovascular and metabolic disease (CVMD) research at CrownBio.

CrownBio provides conventional models that spontaneously develop PKD and closely correlate with human disease, making them an excellent choice for efficacy testing and comparison to existing historical data.

CrownBio also provides unique diabetic nephropathy models that develop kidney disease as part of diabetes complications, a situation reminiscent of the kidney complications arising in diabetic humans, and a major cause of renal failure in type 2 diabetes patients.

CrownBio’s models are unparalleled in their translatability and enable clinically translatable evaluation of therapeutics that target not only kidney complications, but also hyperglycaemia in diabetic patients. This makes these platforms unique in their ability to solve multiple aspects of the complexities of metabolic disease.

'This breadth of in vivo models to support various arms of preclinical renal disease research positions CrownBio as a leader in this field,' said Charles Van Jackson, PhD, General Manager and CSO at PreClinOmics, a Crown Bioscience company.